⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis Biotherapeutics - ResearchAndMarkets.com
businesswire.com
ABBV
INCY
AMGN
PFE
ACRT
Amy Rudolph, PhD, Joins Thryv Therapeutics' Board of Directors to Support Portfolio Progression into Heart Failure
prnewswire.com
PFE
NVS
BMY
ABBV
Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global Care | According to DataM Intelligence
prnewswire.com
GILD
ABBV
MRK
BMY
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
prnewswire.com
ABBV
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
prnewswire.com
ABBV
AbbVie Reports Third-Quarter 2025 Financial Results
prnewswire.com
ABBV
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
prnewswire.com
ABBV
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
prnewswire.com
ABBV
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
prnewswire.com
ABBV
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
prnewswire.com
ABBV